AVTRHealthcare · Medical Instruments & SuppliesThe 16 Wall Street analysts covering Avantor, Inc. hold a median 12-month price target of $14 — -10.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 3 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Avantor, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (94): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (39): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AVTR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −10.2% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | UBS | Maintains | Neutral | $11 → $16 |
| 30 July 2026 | Evercore ISI Group | Maintains | In-Line | $11 → $14 |
| 30 July 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 30 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 30 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $10 → $14 |
| 30 July 2026 | RBC Capital | Maintains | Sector Perform | $9.00 → $14 |
| 30 July 2026 | RBC Capital | Maintains | Sector Perform | — |
| 30 July 2026 | Stifel | Maintains | Hold | — |
| 30 July 2026 | Stifel | Maintains | Hold | $8.00 → $15 |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | $14 → $16 |
| 8 July 2026 | Citigroup | Maintains | Neutral | $9.00 → $11 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 6 July 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 6 July 2026 | Evercore ISI Group | Maintains | In-Line | $8.00 → $11 |
| 26 June 2026 | Bernstein | Reinstates | Market Perform | $11 |
| 24 June 2026 | Barclays | Maintains | Underweight | — |
| 2 June 2026 | Wolfe Research | Assumes | Underperform | $7.00 |
| 15 May 2026 | RBC Capital | Reinstates | Sector Perform | $9.00 |
| 30 Apr 2026 | Citigroup | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVTR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 5 Oct 2026, Avantor, Inc. returned +10.6% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 46% of US stocks
Cheaper than 57% of US stocks
Cheaper than 47% of US stocks
Cheaper than 23% of US stocks
Higher than 28% of US stocks
Higher than 13% of US stocks
Higher than 37% of US stocks
Higher than 59% of US stocks
Higher than 21% of US stocks
Higher than 36% of US stocks
Higher than 63% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Avantor, Inc. has a market value of $10.4B and an enterprise value of $13.8B.
Revenue in the twelve months to 30 June 2026: $6.6B. The latest quarter grew 0.5% year on year.
Net income over the same four quarters: −$578.0M, a −8.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.84.
Free cash flow in the twelve months to 30 June 2026: $454.7M, after $142.3M of capital spending.
Avantor, Inc. spent $79.6M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 14.9×; forward P/E: 17.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Avantor, Inc. employs 13,500 people — $486K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Avantor, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Avantor announced it will release its third quarter 2026 financial results before the market opens on Wednesday, October 28, 2026, followed by a conference call at 8:00 a.m. the same day.
Why it matters — The scheduled earnings release and conference call give Avantor watchers the confirmed date and time to anticipate the company's third-quarter performance update.
A Zacks Investment Research report looks at how Avantor, Inc. (AVTR) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year. The item questions whether medical stocks are lagging Avantor over this period.
Why it matters — A Avantor watcher would want to see how the company's stock has tracked against its sector and peers year to date.
Avantor, Inc. announced the appointment of Todd Garner as Executive Vice President and Chief Financial Officer, effective September 21, 2026. The announcement was made via PRNewswire.
Why it matters — AVTR watchers may care because a new chief financial officer takes on leadership of the company's financial strategy and operations.
Avantor expanded its RIM single-use bioprocessing portfolio across the Asia-Pacific region, increasing access to locally made solutions. The move is part of the company's broader push to grow its bioprocessing business in the region.
Why it matters — Avantor watchers would care because the regional expansion supports the company's bioprocessing growth strategy in the APAC market.
Zacks highlights Avantor's strong second-quarter results, improving orders, and raised 2026 outlook as supporting growth prospects, though it notes concerns from bioprocessing weakness and uneven demand.
Why it matters — AVTR watchers would care because the report points to strengthening fundamentals and an upgraded outlook amid ongoing demand and bioprocessing headwinds.
The 16 Wall Street analysts covering Avantor, Inc. have a median 12-month price target of $14, with estimates ranging from $12 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Avantor, Inc., 2 rate it a Buy, 13 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Avantor, Inc. 82 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Oct 2026, Avantor, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (94 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies -10.2% from the last close, and Ticker Nerd's factor model ranks Avantor, Inc. 82 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Avantor, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVTR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $19 over the next 12 months.
Avantor, Inc. returned +10.6% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Avantor, Inc. is a global life science tools and advanced technology company that supplies mission-critical products and services to customers in biopharma, healthcare, education and government, and applied materials industries.
The most recent item we track (PRNewsWire, 1 Oct 2026): "Avantor® to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026". Avantor announced it will release its third quarter 2026 financial results before the market opens on Wednesday, October 28, 2026, followed by a conference call at 8:00 a.m. the same day.
Avantor, Inc. is a global life science tools and advanced technology company that supplies mission-critical products and services to customers in biopharma, healthcare, education and government, and applied materials industries. Its portfolio includes laboratory chemicals, reagents, consumables, equipment, instrumentation, single-use bioprocessing components, and specialty services that support research, development, production, and quality control. The company also provides customized materials and procurement solutions for highly regulated environments, helping laboratories and production teams maintain consistent workflows across the scientific supply chain. Avantor serves customers across the Americas, Europe, Asia, the Middle East, and Africa, with operations centered in Radnor, Pennsylvania.
CEO Mr. Emmanuel Ligner · 13,500 employees · United States · https://www.avantorsciences.com
